

For Healthcare Professionals: In Case of Emergency

I am currently being treated with ENHERTU

Please contact:

Oncologist Name: _____

Oncologist Telephone: _____



ENHERTU[®]

fam-trastuzumab deruxtecan-nxki
20 mg/mL INJECTION FOR INTRAVENOUS USE

Patients treated with this medication may be at risk for serious and potentially fatal side effects, including:

- Interstitial lung disease/pneumonitis
- Neutropenia
- Cardiac events (eg, left ventricular dysfunction)

This is not a complete list of all potential side effects. Please see the full Prescribing Information, including **Boxed WARNINGS**, and Medication Guide available at www.ENHERTU.com.



Daiichi-Sankyo

AstraZeneca



ENHERTU® is a registered trademark of Daiichi Sankyo Company, Limited.

© 2021 Daiichi Sankyo, Inc. and AstraZeneca. PP-US-EN-0825 01/21